Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
about
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Controlled Human Malaria Infection: Applications, Advances and Challenges.A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.A randomized trial of the prophylactic activity of DSM265 against pre-erythrocytic Plasmodium falciparum controlled human malaria infection by mosquito bites and direct venous inoculation.Assessing drug efficacy against Plasmodium falciparum liver stages in vivo.Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery.Drugs in Development for Malaria.Assessing Plasmodium falciparum transmission in mosquito-feeding assays using quantitative PCR.Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyMalariaSelective Cytotoxicity of Dihydroorotate Dehydrogenase Inhibitors to Human Cancer Cells Under Hypoxia and Nutrient-Deprived ConditionsIsoxazolopyrimidine-Based Inhibitors of Dihydroorotate Dehydrogenase with Antimalarial ActivityChallenges and recent progress in drug discovery for tropical diseases
P2860
Q40106428-7F2CC869-F551-434E-9412-B32EA8BD604BQ44168331-B5DE96AB-C132-496D-B489-836CDDB47B19Q47547431-DEF8361B-820B-47ED-B65C-180F341B736CQ48018719-4749C98C-A6F3-49AA-A60E-2B1836E835F1Q48021575-F8BB8C0A-D197-477A-9996-8DE882AAF49BQ48022169-046421C4-6DAF-4C62-9B5A-4288EB5A22FFQ49927350-DAFC9832-250F-4C79-BF0F-5208AFACE752Q55278895-6AFCD0F1-1F09-4433-84E3-9F9B204D9869Q55662003-59076DAF-5272-4020-85FA-871AE85711E0Q56352603-6CDC02E8-F725-4C46-A547-B5F7F8132213Q56378965-0BF9B3DD-94EA-433E-9E52-7BE14A30AEF8Q58764792-0F797E99-B558-42F2-BCB6-E1274778A709Q58776522-7E0B9830-5578-4531-B10D-5E1DE2222AECQ59073293-EA89ED63-6AE0-4DAD-94F3-23BB403469AB
P2860
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@ast
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@en
type
label
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@ast
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@en
prefLabel
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@ast
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@en
P2093
P2860
P50
P1476
Safety, tolerability, pharmaco ...... phase 1a/1b randomised study.
@en
P2093
Caroline L Ng
Julie Lotharius
Jörg J Möhrle
Kennan Marsh
Lidiya Bebrevska
Louise Marquart
Margaret A Phillips
Maria Rosario
Nathalie Gobeau
Noelle S Williams
P2860
P304
P356
10.1016/S1473-3099(17)30171-8
P577
2017-03-28T00:00:00Z